^
    Back
    Association details:
    Biomarker:BRAF V600
    Cancer:Cutaneous Melanoma
    Drug:Mekinist (trametinib) (MEK inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    …trametinib monotherapy is no longer an NCCN-recommended treatment option due to relatively poor efficacy…
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Melanoma)
    New
    Excerpt:
    Trametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Dabrafenib in combination with trametinib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    A study of GSK1120212 compared with chemotherapy in patients with BRAF mutation positive advanced or metastatic melanoma

    Excerpt:
    ...Histologically confirmed, Stage III unresectable (Stage IIIc) or metastatic (Stage IV) cutaneous melanoma which is also determined to be BRAF V600E/K mutation-positive by the central laboratory. ...
    Trial ID:
    2010-022838-85